Evidence map›Paper›PMID 39911707›Full record

ArticleFrontiers in microbiology2024

Effectiveness of antimicrobial agent combinations against carbapenem-producing

Congcong Liu, Yuchen Wu, Yanyan Zhang, Zelin Yan, Danxia Gu, Hongwei Zhou, Ning Dong, Chang Cai, Gongxiang Chen, Rong Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Molecular Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2026
    Review
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Congcong LiuDepartment of Clinical Laboratory, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Yuchen WuDepartment of Clinical Laboratory, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
Yanyan ZhangDepartment of Clinical Laboratory, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
Zelin YanDepartment of Clinical Laboratory, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
Danxia GuDepartment of Clinical Laboratory, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
Hongwei ZhouDepartment of Clinical Laboratory, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
Ning DongMOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Key Laboratory of Pathogen Bioscience and Anti-infective Medicine, School of Biology & Basic Medical Sciences, Suzhou Medical College, Soochow University, Suzhou, China.
Chang CaiCollege of Animal Science and Technology, College of Veterinary Medicine, Zhejiang Agricultural and Forestry University, Hangzhou, China.
Gongxiang ChenDepartment of Clinical Laboratory, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
Rong ZhangDepartment of Clinical Laboratory, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Carbapenem-resistant Methods: A checkerboard assay involving 24 antimicrobial agent combinations was conducted on 44 strains of carbapenemase-producing CRKP isolated from patients of which 13 CRKP strains carried single KPC variants. The 24 antimicrobial combinations were based on meropenem, polymyxin, tigecycline, ceftazidime/avibactam, respectively. The fractional inhibitory concentration (FIC) indexes were calculated for each combination of antimicrobial agents. Results: The distribution of carbapenemases in 44 CRKP strains was as follows: KPC variants ( Conclusion: Our study suggests that the combinations of antimicrobial agent could serve as potential treatment strategies against CRKP infections. Furthermore, the effectiveness of these combinations is influenced by the types of carbapenemases present. Ceftazidime/avibactam-based combinations have showed superior synergistic effects on KPC variant-producing CRKP strains.

Indexed as

antimicrobial agent combinationscarbapenem-resistant Klebsiella pneumoniaeceftazidime/avibactam-based dual combinationscheckerboard assayKPC variant

Identifiers

PMID39911707
PMCPMC11794265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.